These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22450718)

  • 41. [Long QT syndrome and Brugada syndrome: 2 aspects of the same disease?].
    Cerrone M; Crotti L; Faggiano G; De Michelis V; Napolitano C; Schwartz PJ; Priori SG
    Ital Heart J Suppl; 2001 Mar; 2(3):253-7. PubMed ID: 11307783
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hereditary risk of sudden cardiac death--genetic investigation of the family].
    Lundin C; Platonov P; Kristoffersson U
    Lakartidningen; 2009 Apr 7-21; 106(15-16):1089-93. PubMed ID: 19492675
    [No Abstract]   [Full Text] [Related]  

  • 43. A hot topic: temperature sensitive sodium channelopathies.
    Egri C; Ruben PC
    Channels (Austin); 2012; 6(2):75-85. PubMed ID: 22643347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The skeletal muscle channelopathies: distinct entities and overlapping syndromes.
    Davies NP; Hanna MG
    Curr Opin Neurol; 2003 Oct; 16(5):559-68. PubMed ID: 14501839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of genetics on the clinical management of channelopathies.
    Schwartz PJ; Ackerman MJ; George AL; Wilde AAM
    J Am Coll Cardiol; 2013 Jul; 62(3):169-180. PubMed ID: 23684683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personalized medicine: genetic diagnosis for inherited cardiomyopathies/channelopathies.
    Ackerman MJ; Marcou CA; Tester DJ
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):298-307. PubMed ID: 24775620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiac channelopathies: The role of sodium channel mutations.
    Fonseca DJ; Vaz da Silva MJ
    Rev Port Cardiol (Engl Ed); 2018 Feb; 37(2):179-199. PubMed ID: 29525288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized approach in arrhythmology by genetic-based data: a case report.
    Blokhina AV; Ershova AI; Zyatenkova EV; Meshkov AN; Kiseleva AV; Klimushina MV; Sotnikova EA; Skirko OP; Zharikova AA; Doludin YV; Kharlap MS; Drapkina OM
    Per Med; 2022 Mar; 19(2):83-91. PubMed ID: 35060774
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The importance of variant reinterpretation in inherited cardiovascular diseases: Establishing the optimal timeframe.
    Fernandez-Falgueras A; Coll M; Iglesias A; Tiron C; Campuzano O; Brugada R
    PLoS One; 2024; 19(5):e0297914. PubMed ID: 38691546
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Determining the pathogenicity of genetic variants associated with cardiac channelopathies.
    Campuzano O; Allegue C; Fernandez A; Iglesias A; Brugada R
    Sci Rep; 2015 Jan; 5():7953. PubMed ID: 25608792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue.
    Ackerman MJ
    Heart Rhythm; 2015 Nov; 12(11):2325-31. PubMed ID: 26144349
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ion channelopathies: a tapped-out mine?
    Dudley SC
    Am J Physiol Heart Circ Physiol; 2011 Mar; 300(3):H716-7. PubMed ID: 21193585
    [No Abstract]   [Full Text] [Related]  

  • 53. Precision Medicine and cardiac channelopathies: when dreams meet reality.
    Gnecchi M; Sala L; Schwartz PJ
    Eur Heart J; 2021 May; 42(17):1661-1675. PubMed ID: 33686390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetics update: Monogenetics, polygene disorders and the quest for modifying genes.
    Symonds JD; Zuberi SM
    Neuropharmacology; 2018 Apr; 132():3-19. PubMed ID: 29037745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The fifteen years of discoveries that shaped molecular electrophysiology: time for appraisal.
    Priori SG
    Circ Res; 2010 Aug; 107(4):451-6. PubMed ID: 20724724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic neurological channelopathies: molecular genetics and clinical phenotypes.
    Spillane J; Kullmann DM; Hanna MG
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):37-48. PubMed ID: 26558925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ion channelopathies and migraine pathogenesis.
    Albury CL; Stuart S; Haupt LM; Griffiths LR
    Mol Genet Genomics; 2017 Aug; 292(4):729-739. PubMed ID: 28389699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From gene-discovery to gene-tailored clinical management: 25 years of research in channelopathies and cardiomyopathies.
    Crotti L; Brugada P; Calkins H; Chevalier P; Conte G; Finocchiaro G; Postema PG; Probst V; Schwartz PJ; Behr ER
    Europace; 2023 Aug; 25(8):. PubMed ID: 37622577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heteromeric wild-type/mutant potassium channel subunit composition as a major determinant of channelopathy phenotype in heterozygous patients.
    Brelidze TI
    J Gen Physiol; 2023 Jun; 155(6):. PubMed ID: 37058331
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk stratification in the long-QT syndrome.
    Ellinor PT; Milan DJ; MacRae CA
    N Engl J Med; 2003 Aug; 349(9):908-9; author reply 908-9. PubMed ID: 12944579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.